| アイテムタイプ |
itemtype_ver1(1) |
| 公開日 |
2025-02-03 |
| タイトル |
|
|
タイトル |
Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study) |
|
言語 |
en |
| 著者 |
Kita, Ryosuke
Shimada, Kazuyuki
Machida, Ryunosuke
Sekita, Tetsuya
Sasaki, Keita
Ishitsuka, Kenji
Fukuda, Haruhiko
Maruyama, Dai
Munakata, Wataru
Nagai, Hirokazu
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利 |
|
|
権利情報 |
This is a pre-copyedited, author-produced version of an article accepted for publication in [Japanese Journal of Clinical Oncology] following peer review. The version of record [Ryosuke Kita, Kazuyuki Shimada, Ryunosuke Machida, Tetsuya Sekita, Keita Sasaki, Kenji Ishitsuka, Haruhiko Fukuda, Dai Maruyama, Wataru Munakata, Hirokazu Nagai, Japan Clinical Oncology Group Lymphoma Study Group, Multicenter randomized phase III study of high-dose therapy with autologous stem cell transplantation versus observation for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy (JCOG2210, TRANSFER study), Japanese Journal of Clinical Oncology, 2024;, hyae144, https://doi.org/10.1093/jjco/hyae144] is available online at: https://doi.org/10.1093/jjco/hyae144. |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Patients with peripheral T-cell lymphoma demonstrated a poor prognosis after obtaining a complete response with induction treatment compared to those with B-cell lymphoma. Once it relapsed, curative treatment is frequently limited to invasive treatments with significant treatment-related mortality, including allogeneic stem cell transplantation. The limitations of these treatment choices indicate the necessity for developing optimal consolidation therapies to prevent relapse. This multicenter randomized phase III trial aims to confirm the superiority of the high-dose therapy with autologous stem cell transplantation over observation alone in terms of progression-free survival for patients with newly diagnosed peripheral T-cell lymphoma who achieved complete metabolic response after induction therapy. A total of 140 patients from 52 hospitals will be enrolled in Japan over 5.5 years. This trial is registered in the Japan Registry of Clinical Trials as jRCTs031240169 (https://jrct.niph.go.jp/latest-detail/jRCTs031240169). |
|
言語 |
en |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Online Published: 19 October 2024 |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプresource |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1093/jjco/hyae144 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1465-3621 |
| 書誌情報 |
en : Japanese Journal of Clinical Oncology
巻 55,
号 2,
p. 183-188,
発行日 2025-02
|
| ファイル公開日 |
|
|
日付 |
2025-04-19 |
|
日付タイプ |
Available |
JCOG2210_design_paper.pdf (416 KB)
